Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Open accessThe DOI matches its Crossref record; 134 of the 141 references it cites were found in a registry or an index; 90 of the 190 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To review the evidence about the impact of hypoglycemia on patients with diabetes that has become available since the past reviews of this subject by the American Diabetes Association and The Endocrine Society and to provide guidance about how this new information should be incorporated into clinical practice. PARTICIPANTS: Five members of the American Diabetes Association and five members of The Endocrine Society with expertise in different aspects of hypoglycemia were invited by the Chair, who is a member of both, to participate in a planning conference call and a 2-day meeting that was also attended by staff from both organizations. Subsequent communications took place via e-mail and phone calls. The writing group consisted of those invitees who participated in the writing of the manuscript. The workgroup meeting was supported by educational grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk and sponsorship to the American Diabetes Association from Sanofi. The sponsors had no input into the development of or content of the report. EVIDENCE: The writing group considered data from recent clinical trials and other studies to update the prior workgroup report. Unpublished data were not used. Expert opinion was used to develop some conclusions. CONSENSUS PROCESS: Consensus was achieved by group discussion during conference calls and face-to-face meetings, as well as by iterative revisions of the written document. The document was reviewed and approved by the American Diabetes Association's Professional Practice Committee in October 2012 and approved by the Executive Committee of the Board of Directors in November 2012 and was reviewed and approved by The Endocrine Society's Clinical Affairs Core Committee in October 2012 and by Council in November 2012. CONCLUSIONS: The workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document counseling are provided.
Overview
CoChat Summary
TL;DR
This ADA/Endocrine Society workgroup report updates definitions, risks, and prevention strategies for hypoglycemia in diabetes, with a strong emphasis on avoiding severe episodes and hypoglycemia unawareness. It argues for individualized glycemic targets, better monitoring and education, and further research on outcomes, measurement, and new therapies.
Key findings
- The workgroup defines iatrogenic hypoglycemia as all episodes of abnormally low plasma glucose that expose the person to potential harm, and recommends an alert value of ≤70 mg/dL (≤3.9 mmol/L) for patients at risk; it also classifies episodes as severe, documented symptomatic, asymptomatic, probable symptomatic, or pseudo-hypoglycemia.
- Severe hypoglycemia rates reported in the paper ranged from 115 to 320 per 100 patient-years in type 1 diabetes and 35 to 70 per 100 patient-years in type 2 diabetes; because type 2 diabetes is more common, most hypoglycemia episodes occur in people with type 2 diabetes.
- In ACCORD, intensive glycemic control produced threefold higher hypoglycemia and a 20% increase in mortality; post hoc analyses in ACCORD found severe hypoglycemia had a hazard ratio of 1.41 (95% CI 1.03–1.93) for death.
- In hospitalized patients, one retrospective study found 10.5% of 31,970 general-ward admissions had at least one hypoglycemic episode (≤70 mg/dL), and severe hypoglycemia (≤50 mg/dL) was associated with increased length of stay and greater odds of inpatient death and death within 1 year of discharge.
Methods
- This is a workgroup report/consensus document, not an experimental study; five ADA and five Endocrine Society experts were invited, held a planning call and a 2-day meeting, and developed the manuscript through discussion and iterative revisions.
- The group reviewed recent clinical trials and other studies published since the prior reports; unpublished data were not used, and some conclusions relied on expert opinion.
- Consensus was reached by group discussion and was reviewed/approved by both organizations’ committees in October and November 2012.
Limitations
- The paper states that unpublished data were not used, and that expert opinion was used to develop some conclusions.
- The text makes evident that some evidence is observational, post hoc, or limited by small studies, so causal inference is uncertain in several areas (e.g., mortality, cognition); this is an inference from the paper’s cited evidence, not a limitation explicitly stated in one place.
- The paper explicitly notes gaps in knowledge on hypoglycemia outcomes, mechanisms, and prevention, indicating that several recommendations are based on incomplete evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Valid · 5 Not valid · 33 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“There is convincing evidence that formal training programs that teach patients to replace insulin “physiologically” by giving background and mealtime/correction doses of insulin can reduce the risk of severe hypoglycemia.”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > What strategies are known to prevent hypoglycemia, and what are the clinical recommendations for those at risk for hypoglycemia? > Patient education
What the sources say
- Supportedcites [100] Mühlhauser, 2002, Patient education—evaluation of a complex intervention, Diabetologia source
The Modelling section describes a structured programme teaching patients to adjust insulin doses, using NPH insulin twice daily and regular insulin before meals. The Long-term implementation section reports decreased rates of severe hypoglycaemia in patients with Type I diabetes and says several prospective studies observed that reduction. The paper supports that such programmes can reduce the risk, although not every evaluation found a reduction. (LLM, conf=0.90)
- Partly supportedcites [101] Bott, 1997, Intensified insulin therapy and the risk of severe hypoglycaemia, Diabetologia sourceExperimental — accuracy not yet measured
The Subjects and methods passage describes structured training in background and mealtime insulin dosing, with patients adjusting doses for glucose and carbohydrate intake. The Results and Discussion report fewer severe hypoglycaemic episodes after the programme, but describe the reduction as an association; they do not establish that training itself caused it. The claim’s description of this as convincing evidence that the programmes can reduce risk is therefore stronger than the paper’s finding. (LLM, conf=0.84)
- Supportedcites [102] Sämann, 2005, Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study, Diabetologia source
The Subjects and methods section describes a structured course teaching background insulin injections and meal-by-meal dose adjustments based on blood glucose and carbohydrate intake. The Abstract reports that severe hypoglycaemia fell from 0.37 to 0.14 events per patient per year after training among people with type 1 diabetes. (LLM, conf=0.92)
- Disputedcites [103] DAFNE Study Group, 2002, Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ sourceExperimental — accuracy not yet measured
The skills course section describes training patients to adjust insulin to their meals. But the paper reports that severe hypoglycaemia remained unchanged; the Discussion says there was no significant increase, not a reduction in risk. The claimed risk reduction is therefore contrary to the reported finding. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [104] McIntyre, 2010, Dose adjustment for normal eating (DAFNE)—an audit of outcomes in Australia, Med J Aust source
- Partly supportedcites [105] Hopkins, 2012, Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience, Diabetes Care sourceExperimental — accuracy not yet measured
The Results and Conclusions (pages not provided) report fewer severe hypoglycemia episodes after DAFNE, a structured education program for adults with type 1 diabetes. The paper describes adjusting insulin to carbohydrate intake, but does not specify the claimed background and mealtime/correction-dose teaching. Its evidence is also a retrospective audit based on self-reported hypoglycemia, which qualifies the claim of ‘convincing evidence.’ (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12)”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion states that after an episode of hypoglycemia, the authors found elevated glycemic thresholds for neurogenic and neuroglycopenic symptoms, including in patients with IDDM in the present study. Its terminology indicates that an elevated threshold means symptoms occur at a lower plasma glucose concentration. The Results also report reduced symptom responses after antecedent hypoglycemia. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In critical care units, where the accuracy of POC meters is particularly crucial, their performance may be compromised by medications (vasopressors, acetaminophen), treatments (oxygen), and clinical states (hypotension, anemia) (17).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported? > The challenge of measuring glucose accurately
What the sources say
- Partly supportedcites [17] Klonoff, 2011, Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Section 1.1 Evidence says supplemental oxygen can cause falsely low readings with glucose-oxidase meters and identifies acetaminophen, pressor use, and hypotension as potential concerns for POC testing in critically ill patients. It also reports an accuracy discrepancy among patients with hypotension or pressor treatment. The cited passages do not address anemia as a cause of compromised meter performance. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A single threshold value for plasma glucose concentration that defines hypoglycemia in diabetes cannot be assigned because glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12) and to higher plasma glucose concentrations in patients with poorly controlled diabetes and infrequent hypoglycemia”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion (p. 823) reports that antecedent hypoglycemia changes the glycemic threshold for symptoms in patients with insulin-dependent diabetes. The Discussion also reports symptoms at higher plasma glucose concentrations in patients with poorly or moderately controlled diabetes. Together, these findings support the claim that no single symptom-based plasma glucose threshold applies across these circumstances. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
- Not checked — no full text of the sourcecites [13] Boyle, 1988, Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Hypoglycemia puts patients at risk for injury and death.”
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
“There is no doubt that hypoglycemia can be fatal (26).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Supportedcites [26] Cryer, 2011, Death during intensive glycemic therapy of diabetes: mechanisms and implications, Am J Med source
In the main text (page unavailable), Cryer states that iatrogenic hypoglycemia causes recurrent morbidity in people with diabetes and is sometimes fatal. This supports the broad claim that hypoglycemia puts these patients at risk of harm and death. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
76 more claims · 43 with their cited sources checked
Create a free account to see all 104 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial hyperglycemia and resultant compensatory hyperinsulinemia from high dietary glycemic load can lower plasma glucose to concentrations that compromise brain glucose, w70 mg/dL (3.8 mmol/L) (36), triggering the secretion of autonomic counterregulatory hormones such as adrenaline, cortisol, glucagon, and growth hormone (37).”
From High glycemic index diet as a risk factor for depression: analyses from the Women’s Health Initiative (2015) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risks for hypoglycemia, particularly level 3 hypoglycemia, include longer duration of diabetes, older age, history of recent level 3 hypoglycemia, alcohol ingestion, exercise, lower education levels, lower household incomes (41), chronic kidney disease, and IAH (103-105).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recurrent hypoglycaemia results in an increased likelihood of hypoglycaemia unawareness and subsequent severe hypoglycaemic events, since recurrent hypoglycaemia reduces the glucose concentration that triggers the counter-regulatory responses to return to euglycaemia.106”
From Type 1 diabetes (2018) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“Hypoglycemia is a frequent and dangerous complication of diabetes (1), causing changes in physiological parameters (2,3).”
From Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Individualized glucose targets, patient education, nutrition intervention (e.g., bedtime snack to prevent overnight hypoglycemia when specifically needed to treat low blood glucose), physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve patient outcomes (94).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [94]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Deakin T McShane CE Cade JE Williams RD Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003417 15846663”
Cited work 10.1002/14651858.cd003417.pub2 · retracted 2015-06-30 · notice 10.1002/14651858.cd003417.pub3 · this paper published 2013-04-13
Citations
Cites
1 retracted
Group based training for self-management strategies in people with type 2 diabetes mellitus
Deakin, T. A., McShane, C. E., Cade, J. E., & Williams, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003417.pub2 · Cited by 862
RetractedIntensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In VADT, a recent severe hypoglycemic event was the strongest independent predictor of death at 90 days (3).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 2×
“event of troublesome hypoglycemia (96).”
BackgroundIntensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Research works printed but not linked: 2
- Reno, 2011, Deaths due to severe hypoglycemia are exacerbated by diabetes and ameliorated by hypoglycemic pre-conditioning (Abstract), Diabetes, 60, A81
- Aubert, 1995, Diabetes-Related Hospitalization and Hospital Utilization
Cited by
Items 601–700 of 1,392
Diabetologische Notfälle: Hypoglykämie, ketoazidotisches und hyperglykämisches Koma
Kalscheuer, H., Serfling, G., Schmid, S. M., & Lehnert, H. (2017) · Der Internist · doi:10.1007/s00108-017-0317-x · Cited by 22
Defining relevant hypoglycemia measures in children and adolescents with type 1 diabetes
Jones, T. W., & On behalf of the ISPAD Hypoglycemia Guidelines Writing Group (2017) · Pediatric Diabetes · doi:10.1111/pedi.12600 · Cited by 19
“This aligns with the definition of severe hypoglycemia in adults in accordance with the ADA guidelines.(5) This definition has been to a certain extent problematic in young children because at this age they all may require assistance to correct even mild hypoglycemia.”
BackgroundHypoglycaemia in cystic fibrosis: An analysis of a single centre adult cystic fibrosis clinic
Armaghanian, N., Markovic, T., Brand-Miller, J. C., Bye, P. T. P., Moriarty, C. P., & Steinbeck, K. S. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.11.015 · Cited by 16
Kahsay, H., Fantahun, B., Nedi, T., & Demoz, G. T. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9037374 · Cited by 20
“Other potential factors at this age include the irregular and often difficult eating habits of young children, the sporadic nature of their exercise habits, their inability to identify and alert caregivers about hypoglycemic symptoms, and smaller dose of insulin leading to relatively large increases when errors in dos…”
BackgroundResultKadowaki, T., Wang, G., Rosenstock, J., Yabe, D., Peng, Y., Kanasaki, K., Mu, Y., Mattheus, M., Keller, A., Okamura, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00447-5 · Cited by 16
Bailey, T. S., Willard, J., Klaff, L. J., Stone, J. Y., Melgaard, A. E., & Tehranchi, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14475 · Cited by 16
“Participants were required to have been diagnosed with type 1 diabetes for at least 1 year, with diagnostic criteria as defined by the ADA.10 Participants were furthermore to have been treated with insulin for at least 1 year and be on a stable insulin treatment regimen prior to screening.”
MethodPregnancy outcomes in women with type 1 diabetes using insulin degludec
Ringholm, L., Callesen, N., Damm, P., & Mathiesen, E. R. (2022) · Acta Diabetologica · doi:10.1007/s00592-021-01845-0 · Cited by 17
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
Demmel, V., Sandberg-Schaal, A., Jacobsen, J. B., Golor, G., Pettersson, J., & Flint, A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0442-0 · Cited by 16
“9 mmol/L [70 mg/dL]) according to the American Diabetes Association definition [23] were reported by 10.”
MethodBajpai, S., Cambron‐Mellott, M. J., Peck, E. Y., Poon, J. L., Wang, Q., Mitchell, B. D., Babrowicz, J., Child, C. J., RAIBULET, N. K., & Beusterien, K. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.08.006 · Cited by 17
Choi, S.-Y., & Ko, S. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.327 · Cited by 18
Gad, H., Elgassim, E., Mohammed, I., Alhaddad, A. Y., Aly, H., Cabibihan, J., Al-Ali, A. K., Sadasivuni, K. K., Haji, A., Lamine, N., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0352 · Cited by 18
Дмитриев, И. В., Severina, A. S., Журавель, Н. С., Yevloyeva, M. I., Salimkhanov, R. K., Павловна, Щ. С., Bezunov, E. A., Шамхалова, М. Ш., Semenova, J. F., Klimontov, V. V., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13091606 · Cited by 18
Marx, N., Kolkailah, A. A., Rosenstock, J., Johansen, O. E., Cooper, M. E., Alexander, J. H., Toto, R. D., Wanner, C., Espeland, M. A., Mattheus, M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4602 · Cited by 17
Wang, J., Kang, J., Wu, C., Peng, T., Liao, L., Lee, M., Lee, J., & Chen, S. (2024) · Obesity Reviews · doi:10.1111/obr.13686 · Cited by 15
“The rates of hypoglycemia or severe hypoglycemia episodes, as defined by the American Diabetes Association, 38 are presented in Figure 7.”
BackgroundEfficacy of Insulin Pump Therapy in Elderly Patients
Yeoh, E. C. K., Beato-Víbora, P. I., Rogers, H., Amiel, S. A., & Choudhary, P. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0360 · Cited by 17
Oster, G., Sullivan, S. D., Dalal, M. R., Kazemi, M. R., Rojeski, M., Wysham, C., Sung, J., Johnstone, B. M., Cali, A. M. G., Wei, L. J., et al. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1241663 · Cited by 15
“hypoglycemia in diabetes as BG ≤ 70 mg/dL (see Table 3 for details) [37].”
BackgroundMethodInfluentialSoare, A., Khazrai, Y. M., Fontana, L., Del Toro, R., Lazzaro, M. C., Di Rosa, C., Buldo, A., Fioriti, E., Maddaloni, E., Angeletti, S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.023 · Cited by 15
Johnson, E. L., Frías, J. P., & Trujillo, J. M. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1452515 · Cited by 16
“timely dose adjustments; changing from NPH to a basal analog, and when going beyond further titration of basal insulin, use of lower risk agents, such as GLP-1 RAs, for additional therapy rather than prandial insulin) [32].”
BackgroundOrozco‐Beltrán, D., Artola, S., Jansà, M., de la Torre-Casares, M. L., & Fuster, E. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0875-1 · Cited by 16
“Hypoglycemia, which is defined as blood glucose concentration ≤ 70 mg/dL [7], is typically characterized by its sudden onset and by physical and psychological symptoms such as shakiness, sweating, drowsiness, nausea, poor motor coordination, mental confusion, irritability and loss of consciousness [5].”
BackgroundDewan, N., Shukla, V., Rehni, A. K., Koronowski, K. B., Klingbeil, K. D., Stradecki, H. M., Garrett, T. J., Rundek, T., Pérez‐Pinzón, M. A., & Dave, K. R. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13186 · Cited by 15
Insulin Pump Settings During Breastfeeding in Women with Type 1 Diabetes
Nørgaard, S. K., Nørgaard, K., Roskjær, A. B., Mathiesen, E. R., & Ringholm, L. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0280 · Cited by 17
Diabetes related distress is high in inpatients with diabetes
Kuniß, N., Kramer, G., Müller, U. A., Wolf, G., & Kloos, C. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00659-y · Cited by 18
“9 mmol/l without typical symptoms [18].”
Pathan, M. F., Akter, N., Selim, S., Saifuddin, M., Qureshi, N. K., Kamrul-Hasan, A. B. M., Hannan, M. A., Ahmed, M. A. U., Mustari, M., & Chakraborty, A. K. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s380544 · Cited by 18
“9 mmol/L), and severe hypoglycemia is defined as an event of hypoglycemia characterized by altered mental and/or physical status requiring assistance for recovery.(33,34) Hypoglycaemia episodes include symptomatic episodes (ie, symptoms of dizziness, visual blurring, palpitations, nausea, sweating, confusion, tremor,…”
BackgroundManaging Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies
Demirbilek, H., Vurallı, D., Haris, B., & Hussain, K. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313837 · Cited by 23
“Although a precise glucose value has not been determined to define hypoglycaemia, a glucose value <70 mg/dL has been the point of alert for the clinicians, families and diabetic patients with the risk of hypoglycaemia.(10) Overall, considering the validity of glucose measurement devices, BGM and CGM, which have a low…”
BackgroundResultInfluentialThewjitcharoen, Y., Krittiyawong, S., Wanothayaroj, E., Vongterapak, S., Tawee, A., Kittipoom, W., Nakasatien, S., & Himathongkam, T. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0115-9 · Cited by 17
“The risk of hypoglycemia from treatments presents the greatest significant barrier to optimal glycemic control for the very old patients [9].”
BackgroundSeven-Year Surveillance of the Clinical Performance of a Blood Glucose Test Strip Product
Setford, S. J., Grady, M., Phillips, S., Miller, L., Mackintosh, S., Cameron, H., & Corrigall, K. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817703133 · Cited by 16
Peters, R. M., Lui, M., Patel, K. B., Tian, L., Javaherian, K., Sink, E. M., Xu, R., Xu, Z., Aung, W. Y., Zhou, L. J., et al. (2017) · JMIR Diabetes · doi:10.2196/diabetes.7910 · Cited by 15
Bortolotti, S., Zarantonello, L., Uliana, A., Vitturi, N., Schiff, S., Bisiacchi, P. S., Avogaro, A., Amodio, P., & Maran, A. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.08.005 · Cited by 18
Lee, M. H., Ward, G. M., MacIsaac, R. J., et al. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000841 · Cited by 15
the DEVOTE study group, Pollock, R. F., Valentine, W. J., Marso, S. P., Andersen, A., Gundgaard, J., Hallén, N., Tutkunkardas, D., Magnuson, E. A., & Buse, J. B. (2019) · Applied Health Economics and Health Policy · doi:10.1007/s40258-019-00494-3 · Cited by 18
Sarteau, A. C., Ercolino, G., Muthukkumar, R., Fruik, A., Mayer‐Davis, E. J., & Kahkoska, A. R. (2024) · Diabetes Care · doi:10.2337/dci23-0099 · Cited by 19
Cahn, A., Raz, I., Mosenzon, O., Leibowitz, G., Yanuv, I., Rozenberg, A., Iqbal, N., Hirshberg, B., Sjöstrand, M., Stahre, C., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2763 · Cited by 16
Kefale, A. T. (2016) · Journal of Health, Medicine and Nursing · Cited by 17
Bahia, L., Kupfer, R., Momesso, D., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0206-4 · Cited by 14
Cheng, P. C., Hsu, S. R., Tu, S., Cheng, Y. C., & Liu, Y. H. (2018) · PeerJ · doi:10.7717/peerj.4348 · Cited by 16
“168 PeerJ reviewing PDF | (2017:12:22509:2:0:CHECK 18 Jan 2018) 169 Discussion 170 171 People with T2DM are vulnerable to the detrimental effect of hypoglycemia, which may become 172 a limiting factor in antidiabetic therapy (Seaquist et al., 2013).”
BackgroundSoukup, T., Hull, L., Smith, E. L., Healey, A., Bakolis, I., Amiel, S. A., Sevdalis, N., & PWD Group (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030370 · Cited by 17
Khanimov, I., Boaz, M., Shimonov, M., Wainstein, J., & Leibovitz, E. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.12.026 · Cited by 13
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Wu, C., Ge, Y., Zhang, X., Liu, M., Heng, C., Zhang, L., Du, Y., He, S., Shang, L., & Lang, H. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01790-0 · Cited by 16
“Therefore, it has a significant adverse impact on quality-of-life measures in diabetes [34, 35], which also supported our study’s finding.”
Nørgaard, S. K., Mathiesen, E. R., Nørgaard, K., Clausen, T. D., Damm, P., & Ringholm, L. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045650 · Cited by 17
Murray, E. M., Whellan, D. J., Chen, H., Bertoni, A. G., Duncan, P. W., Pastva, A. M., Kitzman, D. W., & Mentz, R. J. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.08.001 · Cited by 16
Unger, J., Allison, D. C., Kaltoft, M. S., Lakkole, K., Panda, J. K., Ramesh, C. K., Sargın, M., Smolyarchuk, Е. А., Twine, M., Wolthers, B. O., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14566 · Cited by 19
Diabetes: how to manage patients experiencing hypoglycaemia
Lowe, R. N., Williams, B., & Claus, L. W. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-11 · Cited by 27
Rondags, S. M. P. A., de Wit, M., van Tulder, M. W., Diamant, M., & Snoek, F. J. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0035-0 · Cited by 14
“Background Hypoglycaemia is the most common adverse event associated with insulin treatment in type 1 (T1DM) and type 2 diabetes (T2DM) and causes morbidity, a significant reduction in quality of life, and even death [1–3].”
BackgroundKlimontov, V. V., Tsiberkin, A. I., Fazullina, O. N., Александровна, П. М., Tyan, N. V., & Konenkov, V. I. (2014) · Diabetes Mellitus · doi:10.14341/dm2014175-80 · Cited by 13
Management of Diabetes Medications for Patients Undergoing Ambulatory Surgery
Vann, M. A. (2014) · Anesthesiology Clinics · doi:10.1016/j.anclin.2014.02.008 · Cited by 16
Inagaki, N., Harashima, S., Kaku, K., Kondo, K., Maruyama, N., Otsuka, M., Kawaguchi, Y., & Iijima, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13152 · Cited by 15
“In addition to the classification of hypoglycaemia by MedDRA, the classification by a workgroup of the American Diabetes Association and The Endocrine Society was also performed.(22) The “hypoglycaemia” defined by MedDRA is classified into “severe hypoglycaemia,” “documented symptomatic hypoglycaemia,” “probable sympt…”
MethodThe impact of type 1 diabetes on neural activity serving attention
Embury, C. M., Wiesman, A. I., McDermott, T. J., Proskovec, A. L., Heinrichs‐Graham, E., Lord, G. H., Brau, K. L., Drincic, A., Desouza, C. V., & Wilson, T. W. (2018) · Human Brain Mapping · doi:10.1002/hbm.24431 · Cited by 16
“…type 1 diabetes is well-known throughout the literature (Cryer, 2014, 2017; Grober et al., 2011; Hansen et al., 2017; Rooijackers et al., 2016; Seaquist et al., 2013), with these patients experiencing two hypoglycemic episodes on average weekly and an annual incidence of severe hypoglycemia…”
BackgroundTiruneh, G. G., Abebe, N., & Dessie, G. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0341-z · Cited by 19
“A report of a workgroup of the American diabetes association and the Endocrine society states that the incidence of iatrogenic hypoglycemia increases with the duration of diabetes [4].”
BackgroundMethodInfluentialVillani, M., Earnest, A., Smith, K. L., Giannopoulos, D., Soldatos, G., de Courten, B. V., & Zoungas, S. (2019) · Diabetologia · doi:10.1007/s00125-019-4933-y · Cited by 16
Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE
Heller, S. R., Lingvay, I., Marso, S. P., Philis‐Tsimikas, A., Pieber, T. R., Poulter, N. R., Pratley, R. E., HACHMANN-NIELSEN, E., Kvist, K., Lange, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14049 · Cited by 15
“Strengths of this analysis include use of a large, double-blind trial with a high retention rate, independent adjudication of cardiovascular and severe hypoglycaemic events, and use of a standard, robust definition of severe hypoglycaemia according to international guidelines.(22)”
MethodSelf-citationHypoglycemia, Malnutrition and Body Composition
Khanimov, I., Shimonov, M., Wainstein, J., & Leibovitz, E. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_526 · Cited by 14
Bishay, R. H., & Suryawanshi, A. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/7390927 · Cited by 14
Kloos, C., Burghardt, K., Müller, U. A., Kramer, G., Muller, N., Wolf, G., & Kuniß, N. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0983-1559 · Cited by 16
Predictors for Mild and Severe Hypoglycemia in Insulin-Treated Japanese Diabetic Patients
Sonoda, N., Morimoto, A., Ugi, S., Morino, K., Sekine, O., Nemoto, K.-I., Godai, K., Maegawa, H., & Miyamatsu, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130584 · Cited by 16
“In this study, hypoglycemia was defined as a blood glucose level of 70 mg/dl [22].”
MethodComparative effectiveness and safety of different basal insulins in a real-world setting
Ji, L., Zhang, P., Zhu, D., Lu, J., Guo, X., Wu, Y., Li, X., Ji, J., Jia, W., Yang, W., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12920 · Cited by 13
“Hypoglycaemia was classified as severe or minor (documented symptomatic, asymptomatic, probable symptomatic and pseudo hypoglycaemia) according to recommendations of the American Diabetes Association.(23) Unlike data from visit 3, most FPG and HbA1c data at visit 2 were self-reported.”
MethodEscalada, J., Liao, L., Pan, C., Wang, H., & BALA, M. M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1189893 · Cited by 15
The Role of Platelets in Hypoglycemia-Induced Cardiovascular Disease: A Review of the Literature
Ali, A. A. G., Niinuma, S. A., Moin, A. S. M., Atkin, S. L., & Butler, A. E. (2023) · Biomolecules · doi:10.3390/biom13020241 · Cited by 14
“Such approaches are likely to prove most beneficial for patients such as those with hypoglycemia unawareness as a result of cognitive impairment or hypoglycemia-induced autonomic failure, and patients with comorbidities such as renal impairment and liver failure [86,89].”
BackgroundMatsumoto, S., Abalovich, A., Wynyard, S., Carulla, M. E., & Abalovich, D. (2023) · Xenotransplantation · doi:10.1111/xen.12798 · Cited by 13
Verhulst, C. E. M., van Heck, J. I. P., Fabricius, T. W., Stienstra, R., Teerenstra, S., McCrimmon, R. J., Tack, C. J., Pedersen‐Bjergaard, U., & de Galan, B. E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15205 · Cited by 14
“betes experience, on average, one to three hypoglycaemic events per week and one severe hypoglycaemic event per year.(2,3) Recurrent hypoglycaemic episodes can attenuate the counterregulatory response, and result in impaired awareness of hypoglycaemia (IAH).”
BackgroundGruessner, R. W. G., & Gruessner, A. C. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.06.004 · Cited by 12
Drug treatment for diabetes in nursing home residents
Barreto, P. D. S., Sanz, C., Vellas, B. J., Lapeyre‐Mestre, M., & Rolland, Y. (2013) · Diabetic Medicine · doi:10.1111/dme.12354 · Cited by 15
Avoiding hypoglycaemia: a new target of care for elderly diabetic patients
Wong, C. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144494 · Cited by 17
Intensive glycemic control in younger and older U.S. adults with type 2 diabetes
Casagrande, S. S., Cowie, C. C., & FRADKIN, J. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.006 · Cited by 15
Genetic determinants of impaired awareness of hypoglycemia in type 1 diabetes
Schouwenberg, B. J., Coenen, M. J. H., Paterson, A. D., Tack, C. J., Smits, P., Kramers, C., & de Galan, B. E. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000295 · Cited by 17
Diallo, A. M., Novella, J., Lukas, C., Souchon, P., Dramé, M., François, M., Decoudier, B., Barraud, S., Salmon-Musial, A. S., Ancelle, D., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.05.011 · Cited by 18
Brož, J., Žďarská, D. J., Štěpánová, R., & Kvapil, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0584-8 · Cited by 15
Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus
Frier, B. M., Ratzki‐Leewing, A. A., & Harris, S. B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13732 · Cited by 12
Frías, J. P., González-Gálvez, G., JOHNSSON, E. K., Maaske, J., Testa, M. A., Simonson, D. C., Dronamraju, N., García‐Sánchez, R., & Peters, A. L. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13997 · Cited by 15
Watada, H., Yamauchi, T., Yamamoto, F., Taniguchi, A., Yarush, L., Heilmann, C. J., & Yasui, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1782884 · Cited by 13
Russell, S. J., BALLIRO, C. A., Ekelund, M., El-Khatib, F. H., Graungaard, T., Greaux, E. G., HILLARD, M. A., Jafri, R. Z., Rathor, N., SELAGAMSETTY, R., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01087-x · Cited by 16
Gregory, J. W., Carter, K., Cheung, W., Holland, G., Bowen‐Morris, J., Luzio, S. D., Dunseath, G. J., Tree, T. I. M., Yang, J. H. M., Marwaha, A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049595 · Cited by 15
The future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?
Naqvi, R. A., Naqvi, A. R., Singh, A. R., Priyadarshini, M., Balamurugan, A. N., & Layden, B. T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1001041 · Cited by 19
“glucose stimulation (3); pigs are easily bred, sacrificed for food, and have large litters with offspring that rapidly attain adult size (4); pig islets, if coming from a single donor, could be more consistent as compared with human cadaveric islets that have different degrees of functionality, cold ischemia injury, a…”
BackgroundMethodLiatis, S., Mylona, M., Kalopita, S., Papazafiropoulou, A. K., Karamagkiolis, S., Melidonis, A. J., Xilomenos, A., Ioannidis, I., Kaltsas, G., Lanaras, L., et al. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.10.006 · Cited by 13
Goldstein, D., Chodick, G., Shalev, V., Thorsted, B. L., Elliott, L., & Karasik, A. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0169-8 · Cited by 15
“Moreover, hypoglycemia is associated with death, adverse cardiovascular outcomes, dementia, falls, and fractures [9].”
BackgroundChou, W.-Y., Li, Y., Chan, W.-K., & Chen, S. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.10.005 · Cited by 15
“[11] Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.”
BackgroundSaydah, S., Imperatore, G., Divers, J., Bell, R. A., Henkin, L. F., Mayer‐Davis, E. J., Zhong, V. W., Dabelea, D., Lawrence, J. M., & Pihoker, C. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.57 · Cited by 13
Nigam, A., Varun, N., Sharma, S., Munjal, Y. P., & Prakash, A. (2019) · Obstetric Medicine · doi:10.1177/1753495x18807549 · Cited by 15
Li, P., Geng, Z., Ladage, V. P., Wu, J., Lorincz, I., & Doshi, J. A. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13832 · Cited by 13
“Older patients make up the majority of patients with type 2 diabetes and are at a higher risk of hypoglycaemia because of a number of factors, including age-related changes in renal and hepatic metabolism, co-morbid illness, and polypharmacy.(3,16) Even mild cognitive dysfunction might increase the risk of experiencin…”
BackgroundMartyn-Nemeth, P. A., Duffecy, J. L., Quinn, L., Park, C., Mihailescu, D. V., & Penckofer, S. M. (2019) · Trials · doi:10.1186/s13063-019-3876-4 · Cited by 16
High concurrent use of sulfonylureas and antimicrobials with drug interactions causing hypoglycemia
Pilla, S. J., Pitts, S. I., & Maruthur, N. M. (2022) · Journal of Patient Safety · doi:10.1097/pts.0000000000000739 · Cited by 12
“Reasonable strategies include educating patients and their caregivers on the potential for hypoglycemia and how to manage hypoglycemic events that do occur, increasing the patient’s glucose self-monitoring, and considering temporarily dose-reducing or holding sulfonylureas.(52) Incorporating such recommendations into…”
BackgroundRoth, J., Muller, N., Lehmann, T., Böer, K., Lobel, S. A., Pum, J. K. W., & Müller, U. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-110053 · Cited by 12
Yang, T., Ziemba, R. E., Shehab, N., Geller, A. I., Talreja, K., Campbell, K. N., & Budnitz, D. S. (2022) · Medical Care · doi:10.1097/mlr.0000000000001682 · Cited by 12
Lin, Y. K., Ye, W., Hepworth, E., Agni, A., MATUS, A. M., Flatt, A. J., Shaw, J., Rickels, M. R., Amiel, S. A., & Speight, J. (2024) · Diabetologia · doi:10.1007/s00125-024-06310-5 · Cited by 13
“[27].”
Leelarathna, L., Dellweg, S., Mader, J. K., Barnard, K. D., Benesch, C., Ellmerer, M., Heinemann, L., Kojzar, H., Thabit, H., Wilinska, M. E., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-006075 · Cited by 14
Long-Term Prediction of Severe Hypoglycemia in Type 1 Diabetes: Is It Really Possible?
Henriksen, M. M., Færch, L., Thorsteinsson, B., & Pedersen‐Bjergaard, U. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816664745 · Cited by 13
Hypoglycemic episodes in cats with diabetes mellitus: 30 cases (2013–2015)
Viebrock, K. A., & Dennis, J. (2017) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x17722853 · Cited by 18
Pollock, R. F., Valentine, W. J., Marso, S. P., Gundgaard, J., Hallén, N., Hansen, L., Tutkunkardas, D., Buse, J. B., & On behalf of the DEVOTE Study Group (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0430-4 · Cited by 12
“* Severe hypoglycemia was defined according to the American Diabetes Association as an episode requiring the assistance of another person to actively administer carbohydrate or glucagon or to take other corrective actions [30].”
BackgroundSamuel, S., Goswami, D., Shum, K., Boye, K. S., Rengarajan, B., Curtis, B. H., & Curtis, S. E. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1020363 · Cited by 13
Jha, S., Dogra, S., Yadav, A., Siddiqui, S., Panda, M., Srivastava, K., Raghuvanshi, L., Kaur, S., Bhargava, A., Mathur, R., et al. (2016) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-016-0501-x · Cited by 12
Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment
Karaglani, M., Ragia, G., Παναγοπούλου, Μ., Balgkouranidou, I., Nena, E., Kolios, G. C., Παπάνας, Ν., Manolopoulos, V. G., & Chatzaki, Ε. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-121265 · Cited by 14
Agesen, R. M., Alibegovic, A. C., Andersen, H. U., Beck‐Nielsen, H., Gustenhoff, P., Hansen, T. K., Hedetoft, C., Jensen, T. J., Juhl, C. B., Lerche, S. S., et al. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0408-x · Cited by 13
“These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma [15].”
BackgroundEvans, M., Moes, R. G. J., Pedersen, K. S., Gundgaard, J., & Pieber, T. R. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01332-y · Cited by 14
Uemura, F., Okada, Y., Torimoto, K., & Tanaka, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83999-z · Cited by 13
Porcellati, F., Mauro, S. D., Mazzieri, A., Scamporrino, A., Filippello, A., Fano, M. D., Fanelli, C. G., Purrello, F., Malaguarnera, R., & Piro, S. (2021) · Biomolecules · doi:10.3390/biom11091281 · Cited by 19
“recurrent), and presence of comorbidities, can cause a plethora of severe consequences [11].”
BackgroundMethodInfluentialEducating Patients About Hypoglycemia Prevention and Self-Management
Unger, J. (2013) · Clinical Diabetes · doi:10.2337/diaclin.31.4.179 · Cited by 13
Saulnier, P., Briet, C., Gand, E., Chaillous, L., Dubois, S. G., Bonnet, F., Leguerrier, A.-M., Fradet, G., Crespin, I. D., Kerlan, V., et al. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.003 · Cited by 14
Benning, T. J., Heien, H. C., Herges, J. R., Creo, A. L., Al Nofal, A., & McCoy, R. G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111026 · Cited by 11
Revisiting hypoglycemia in diabetes
Gehlaut, R. R., & Shubrook, J. H. (2013) · Osteopathic Family Physician · doi:10.1016/j.osfp.2013.08.002 · Cited by 11
Bain, S. C., Belmar, N., Hoff, S. T., Husain, M., Rasmussen, S., Vilsbøll, T., & Petrie, M. C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01659-7 · Cited by 17
Metadata
- Authors
- Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R.
- Affiliations
- University of Minnesota (US)
- The Frist Clinic, Nashville, Tennessee;
- Mid-America Diabetes Associates, Wichita, Kansas; the
- Washington University in St. Louis (US)
- University of Tennessee Health Science Center (US)
- Park Nicollet Clinic (US)
- University of Sheffield (GB)
- University of South Florida (US)
- Boston University (US)
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Seaquist, Elizabeth R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1384-1395
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631867
- OpenAlex
- W2109416725
- Cited by
- 1,389
- References
- 141
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 62 · 2023: 66 · 2022: 92 · 2021: 127 · 2020: 119 · 2019: 149 · 2018: 148 · 2017: 151 · 2016: 129 · 2015: 129 · 2014: 92 · 2013: 33
- FWCI
- 100.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- National Institute for Health and Care Research (NF-SI-0611-10248)
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, diabetes mellitus, hypoglycemia definition, hypoglycemia prevention, long-term outcomes, patient counseling, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemia, Societies, Medical, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.